Now the two companies are saying the supply pact will expand to all of CSL’s donation centers, spanning more than 300 in the U.S., with a plan to fully transition to Haemonetics’ NexSys PCS platform by the end of 2027.
It’s a return to form for Haemonetics, which previously supplied CSL’s U.S. network with its PCS2 plasma collection systems. That contract expired in mid-2022 and was not renewed — taking about one-eighth of Haemonetics business at the time, with about $117 million logged in the 2020 fiscal year.
After that, CSL relied on Terumo BCT’s automated Rika collection machines for the U.S. — the competitor celebrated the completion of an 18-month rollout just last year — while Haemonetics maintained its relationship with CSL’s European plasma business.
In a statement, CSL said it has signed a new transition deal with Terumo as it makes the switch to NexSys, which received its most recent clearance from the FDA earlier this year. The system includes Haemonetics’ Persona PLUS technology, aimed to boost the average plasma volume by tailoring settings for each donor.
Terumo said the decision to terminate its supply agreement was mutual, and estimated the total cost of the lost business at $610 million, with about $450 million representing impairment charges related to U.S.-based manufacturing equipment. About $160 million will cover the losses during the transition period and eventual restructuring.
Haemonetics said the full scope and timing of the expanded deal are still subject to change as the final details are hammered out, according to a filing with the SEC. At this time the company is not making any changes to its previous financial guidance, though its second-quarter earnings report for fiscal 2027 is scheduled for November 5.
Haemonetics’ stock jumped about 17% on the news, to about $119 per share.
